Breast Cancer Research最新文献

筛选
英文 中文
Uncovering immune cell-associated genes in breast cancer: based on summary data-based Mendelian randomized analysis and colocalization study. 揭示乳腺癌中免疫细胞相关基因:基于汇总数据的孟德尔随机分析和共定位研究。
IF 7.4 1区 医学
Breast Cancer Research Pub Date : 2024-11-29 DOI: 10.1186/s13058-024-01928-0
Jingyang Liu, Wen Sun, Ning Li, Haibin Li, Lijuan Wu, Huan Yi, Jianguang Ji, Deqiang Zheng
{"title":"Uncovering immune cell-associated genes in breast cancer: based on summary data-based Mendelian randomized analysis and colocalization study.","authors":"Jingyang Liu, Wen Sun, Ning Li, Haibin Li, Lijuan Wu, Huan Yi, Jianguang Ji, Deqiang Zheng","doi":"10.1186/s13058-024-01928-0","DOIUrl":"10.1186/s13058-024-01928-0","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer, which is the most prevalent form of cancer among women globally, encompasses various subtypes that demand distinct treatment approaches. The tumor microenvironment and immune response are of crucial significance in the development and progression of breast cancer. Nevertheless, there has been scant evidence concerning the genes within breast cancer - specific immune cells.</p><p><strong>Methods: </strong>We utilized summary data-based Mendelian randomization (SMR) to identify genes associated with breast cancer by utilizing expression quantitative trait loci (eQTL) datasets for 14 different immune cell types and genome-wide association studies (GWAS) for overall breast cancer and its subtypes. Furthermore, colocalization analysis was carried out to evaluate whether the observed association in SMR analyses is influenced by the same causal variant. Replication analysis and bulk RNA sequencing (bulkRNA-seq) analysis were employed to validate promising immune genes as potential drug targets.</p><p><strong>Results: </strong>After correcting for the rate of false discovery, we discovered a total of 17 genes in 9 immune cell types that were significantly associated with overall breast cancer and its subtypes. The genes KCNN4, L3MBTL3, ZBTB38, MDM4, and TNFSF10 were identified in overall breast cancer and its subtypes. Colocalization analyses provided robust evidence in support of these associations. Notably, the KCNN4 gene in non-classical MONOcytes (MONOnc) was further validated through replication analysis and bulkRNA-seq analysis.</p><p><strong>Conclusion: </strong>In summary, our research has revealed a repertoire of genes within diverse immune cells associated with breast cancer. KCNN4 gene in non-classical MONOcytes (MONOnc) exhibited a negative association with overall breast cancer and its subtypes, which was identified as a potential drug target for breast cancer, opening up new avenues for therapeutic interventions.</p>","PeriodicalId":49227,"journal":{"name":"Breast Cancer Research","volume":"26 1","pages":"172"},"PeriodicalIF":7.4,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11606077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Quantification of intratumoral heterogeneity using habitat-based MRI radiomics to identify HER2-positive, -low and -zero breast cancers: a multicenter study. 校正:使用基于栖息地的MRI放射组学来确定her2阳性、低和零乳腺癌的肿瘤内异质性量化:一项多中心研究。
IF 7.4 1区 医学
Breast Cancer Research Pub Date : 2024-11-29 DOI: 10.1186/s13058-024-01938-y
Haoquan Chen, Yulu Liu, Jiaqi Zhao, Xiaoxuan Jia, Fan Chai, Yuan Peng, Nan Hong, Shu Wang, Yi Wang
{"title":"Correction: Quantification of intratumoral heterogeneity using habitat-based MRI radiomics to identify HER2-positive, -low and -zero breast cancers: a multicenter study.","authors":"Haoquan Chen, Yulu Liu, Jiaqi Zhao, Xiaoxuan Jia, Fan Chai, Yuan Peng, Nan Hong, Shu Wang, Yi Wang","doi":"10.1186/s13058-024-01938-y","DOIUrl":"10.1186/s13058-024-01938-y","url":null,"abstract":"","PeriodicalId":49227,"journal":{"name":"Breast Cancer Research","volume":"26 1","pages":"173"},"PeriodicalIF":7.4,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11605847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metastatic recurrence in women diagnosed with non-metastatic breast cancer: a systematic review and meta-analysis. 被诊断为非转移性乳腺癌妇女的转移性复发:系统回顾和荟萃分析。
IF 7.4 1区 医学
Breast Cancer Research Pub Date : 2024-11-27 DOI: 10.1186/s13058-024-01881-y
Eileen Morgan, Colette O'Neill, Richa Shah, Oliver Langselius, Yaqi Su, Clara Frick, Hanna Fink, Aude Bardot, Paul M Walsh, Ryan R Woods, Lou Gonsalves, Jan F Nygård, Serban Negoita, Esmeralda Ramirez-Pena, Karen Gelmon, Nicoleta Antone, Miriam Mutebi, Sabine Siesling, Fatima Cardoso, Julie Gralow, Isabelle Soerjomataram, Melina Arnold
{"title":"Metastatic recurrence in women diagnosed with non-metastatic breast cancer: a systematic review and meta-analysis.","authors":"Eileen Morgan, Colette O'Neill, Richa Shah, Oliver Langselius, Yaqi Su, Clara Frick, Hanna Fink, Aude Bardot, Paul M Walsh, Ryan R Woods, Lou Gonsalves, Jan F Nygård, Serban Negoita, Esmeralda Ramirez-Pena, Karen Gelmon, Nicoleta Antone, Miriam Mutebi, Sabine Siesling, Fatima Cardoso, Julie Gralow, Isabelle Soerjomataram, Melina Arnold","doi":"10.1186/s13058-024-01881-y","DOIUrl":"10.1186/s13058-024-01881-y","url":null,"abstract":"<p><strong>Background: </strong>To assess proportions of metastatic recurrence in women initially diagnosed with non-metastatic breast cancer by stage at diagnosis, breast cancer subtype, calendar period and age.</p><p><strong>Methods: </strong>A systematic search of MEDLINE and Web of Science databases (January 2010-12 May 2022) was conducted. Studies reporting the proportion of distant metastatic recurrence in women with non-metastatic breast cancer were identified and outcomes and characteristics were extracted. Risk of bias was assessed independently by two reviewers. Random-effects meta-analyses of proportions were used to calculate pooled estimates and 95% confidence intervals (CIs).</p><p><strong>Results: </strong>193 studies covering over 280,000 patients were included in the main analysis. Pooled proportions of metastatic recurrence increased with longer median follow-up time from 12.2% (95% CI 10.5-14.0%) at 1-4 years post diagnosis, 14.3% (95% CI 12.9-15.7%) at 5-9 years to 23.3% (95% CI 20.1-26.8) at 10 years or more. Regional variation was observed with pooled estimates ranging from 11.0% (95% CI 8.5-13.7%) in Europe to 26.4% (95% CI 16.7-37.4%) in Africa (1-4 years follow-up). Proportions of recurrence were higher in studies with diagnosis before 2000 (22.2%, 95% CI 15.1-30.3) compared to studies with diagnosis from 2000 onwards (12.8%, 95% CI 11.7-14.0). At 1-4 years median follow-up, pooled proportions of metastatic recurrence were higher in women with hormone receptor negative (15.2%, 95% CI 12.0-18.7%) compared with receptor positive disease (9.6%, 95% CI 6.2-13.6%) and in women with locally advanced (33.2%, 95% CI 24.7-42.3%) relative to early disease at initial diagnosis (4.8%, 95% CI 2.5-7.8%). Proportions were higher in those under 50 years compared with 70+ years, 18.6% (95% CI 15.9-21.4%) versus 13.3% (95% CI 9.2, 18.0%), respectively. Heterogeneity was high in all meta-analyses and results should be interpreted with caution.</p><p><strong>Conclusions: </strong>Higher proportions of metastatic recurrence in patients initially diagnosed at an advanced stage and in earlier calendar period emphasises the importance of early detection and treatment advancements. As the global number of breast cancer survivors increases, research and health policy efforts should be directed towards timely diagnosis and access to effective treatments and care.</p><p><strong>Study registration: </strong>PROSPERO CRD42022314500.</p>","PeriodicalId":49227,"journal":{"name":"Breast Cancer Research","volume":"26 1","pages":"171"},"PeriodicalIF":7.4,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11603627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Loss of chromosome cytoband 13q14.2 orchestrates breast cancer pathogenesis and drug response. 染色体细胞带 13q14.2 的缺失协调了乳腺癌的发病机制和药物反应。
IF 7.4 1区 医学
Breast Cancer Research Pub Date : 2024-11-27 DOI: 10.1186/s13058-024-01924-4
Parastoo Shahrouzi, Youness Azimzade, Wioletta Brankiewicz-Kopcinska, Sugandha Bhatia, David Kunke, Derek Richard, Xavier Tekpli, Vessela N Kristensen, Pascal H G Duijf
{"title":"Loss of chromosome cytoband 13q14.2 orchestrates breast cancer pathogenesis and drug response.","authors":"Parastoo Shahrouzi, Youness Azimzade, Wioletta Brankiewicz-Kopcinska, Sugandha Bhatia, David Kunke, Derek Richard, Xavier Tekpli, Vessela N Kristensen, Pascal H G Duijf","doi":"10.1186/s13058-024-01924-4","DOIUrl":"10.1186/s13058-024-01924-4","url":null,"abstract":"<p><p>Breast cancer (BCa) is a major global health challenge. The BCa genome often carries extensive somatic copy number alterations (CNAs), including gains/amplifications and losses/deletions. These CNAs significantly affect tumor development, drug response and patient survival. However, how individual CNAs contribute is mostly elusive. We identified loss of chromosome 13q14.2 as a key CNA in BCa, occurring in up to 63% of patients, depending on the subtype, and correlating with poor survival. Through multi-omics and in vitro analyses, we uncover a paradoxical role of 13q14.2 loss, promoting both cell cycle and pro-apoptotic pathways in cancer cells, while also associating with increased NK cell and macrophage populations in the tumor microenvironment. Notably, 13q14.2 loss increases BCa susceptibility to BCL2 inhibitors, both in vitro and in patient-derived xenografts. Thus, 13q14.2 loss could serve as a biomarker for BCa prognosis and treatment, potentially improving outcomes for BCa patients.</p>","PeriodicalId":49227,"journal":{"name":"Breast Cancer Research","volume":"26 1","pages":"170"},"PeriodicalIF":7.4,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11600738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis. 更正:在 2,295 例 HR + HER2- 乳腺癌中使用 21 基因多基因检测法区分 HER2 低和 HER2 零肿瘤:一项回顾性分析。
IF 7.4 1区 医学
Breast Cancer Research Pub Date : 2024-11-26 DOI: 10.1186/s13058-024-01929-z
Yoonwon Kook, Young-Jin Lee, Chihhao Chu, Ji Soo Jang, Seung Ho Baek, Soong June Bae, Yoon Jin Cha, Gyungyup Gong, Joon Jeong, Sae Byul Lee, Sung Gwe Ahn
{"title":"Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis.","authors":"Yoonwon Kook, Young-Jin Lee, Chihhao Chu, Ji Soo Jang, Seung Ho Baek, Soong June Bae, Yoon Jin Cha, Gyungyup Gong, Joon Jeong, Sae Byul Lee, Sung Gwe Ahn","doi":"10.1186/s13058-024-01929-z","DOIUrl":"10.1186/s13058-024-01929-z","url":null,"abstract":"","PeriodicalId":49227,"journal":{"name":"Breast Cancer Research","volume":"26 1","pages":"164"},"PeriodicalIF":7.4,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11590534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142733948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Plasma prolactin and postmenopausal breast cancer risk: a pooled analysis of four prospective cohort studies. 血浆催乳素与绝经后患乳腺癌的风险:对四项前瞻性队列研究的汇总分析。
IF 7.4 1区 医学
Breast Cancer Research Pub Date : 2024-11-26 DOI: 10.1186/s13058-024-01922-6
Jacob K Kresovich, Catherine Guranich, Serena Houghton, Jing Qian, Micheal E Jones, Maegan E Boutot, Mitch Dowsett, A Heather Eliassen, Montserrat Garcia-Closas, Peter Kraft, Aaron Norman, Michael Pollak, Sabina Rinaldi, Bernard Rosner, Minouk J Schoemaker, Christopher Scott, Anthony J Swerdlow, Roger L Milne, Shelley S Tworoger, Celine M Vachon, Susan E Hankinson
{"title":"Plasma prolactin and postmenopausal breast cancer risk: a pooled analysis of four prospective cohort studies.","authors":"Jacob K Kresovich, Catherine Guranich, Serena Houghton, Jing Qian, Micheal E Jones, Maegan E Boutot, Mitch Dowsett, A Heather Eliassen, Montserrat Garcia-Closas, Peter Kraft, Aaron Norman, Michael Pollak, Sabina Rinaldi, Bernard Rosner, Minouk J Schoemaker, Christopher Scott, Anthony J Swerdlow, Roger L Milne, Shelley S Tworoger, Celine M Vachon, Susan E Hankinson","doi":"10.1186/s13058-024-01922-6","DOIUrl":"10.1186/s13058-024-01922-6","url":null,"abstract":"<p><strong>Background: </strong>Prolactin, a hormone produced by the pituitary gland, regulates breast development and may contribute to breast cancer etiology. However, most epidemiologic studies of prolactin and breast cancer have been restricted to single, often small, study samples with limited exploration of effect modification.</p><p><strong>Methods: </strong>The Biomarkers in Breast Cancer Risk Prediction consortium includes 8,279 postmenopausal women sampled from four prospective cohort studies, of whom 3,441 were diagnosed with invasive breast cancer after enrollment. Prolactin concentrations were measured for all study participants on plasma samples collected when all women were postmenopausal and before any breast cancer diagnosis using ELISA assays. Pooled, unconditional logistic regression models, adjusted for confounders, estimated odd ratios (OR) for associations of prolactin and postmenopausal breast cancer risk overall and stratified by breast cancer risk factors.</p><p><strong>Results: </strong>Higher plasma prolactin concentrations were positively associated with postmenopausal breast cancer risk (> 13.2 ng/mL vs. < 7.9 ng/mL, OR: 1.20, 95% CI: 1.06, 1.36; P-trend < 0.001). Although associations did not appear to vary by time since blood draw or most breast cancer risk factors, associations were primarily observed in current users of postmenopausal hormones at blood draw (> 13.2 ng/mL vs. < 7.9 ng/mL, current users, OR: 1.58, 95% CI: 1.27, 1.96, P-trend < 0.001; non-current users, OR: 1.08, 95% CI: 0.93, 1.27, P-trend = 0.11; P-heterogeneity = 0.06).</p><p><strong>Conclusion: </strong>Prolactin may be a risk factor for postmenopausal breast cancer, particularly in the context of postmenopausal hormone use. Investigations of prolactin interactions with other hormonal factors may further inform breast cancer etiology.</p>","PeriodicalId":49227,"journal":{"name":"Breast Cancer Research","volume":"26 1","pages":"169"},"PeriodicalIF":7.4,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11590566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142733951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Longitudinal history of mammographic breast density and breast cancer risk by familial risk, menopausal status, and initial mammographic density level in a high risk cohort: a nested case-control study. 高风险队列中按家族风险、绝经状态和初始乳腺 X 线照相密度水平划分的乳腺 X 线照相密度纵向历史和乳腺癌风险:一项巢式病例对照研究。
IF 7.4 1区 医学
Breast Cancer Research Pub Date : 2024-11-26 DOI: 10.1186/s13058-024-01917-3
Parisa Tehranifar, Erica J Lee Argov, Shweta Athilat, Yuyan Liao, Ying Wei, Alexandra J White, Katie M O'Brien, Dale P Sandler, Mary Beth Terry
{"title":"Longitudinal history of mammographic breast density and breast cancer risk by familial risk, menopausal status, and initial mammographic density level in a high risk cohort: a nested case-control study.","authors":"Parisa Tehranifar, Erica J Lee Argov, Shweta Athilat, Yuyan Liao, Ying Wei, Alexandra J White, Katie M O'Brien, Dale P Sandler, Mary Beth Terry","doi":"10.1186/s13058-024-01917-3","DOIUrl":"10.1186/s13058-024-01917-3","url":null,"abstract":"<p><strong>Background: </strong>Elevated mammographic density is associated with increased breast cancer risk. However, the contribution of longitudinal changes in mammographic density to breast cancer risk beyond initial mammographic density levels, considering familial breast cancer risk and menopausal status, remains uncertain but holds important clinical implications.</p><p><strong>Methods: </strong>In a nested case-control study within the Sister Study (323 cases, 899 controls; 12,095 mammograms), a cohort enriched for family history of breast cancer, we examined case-control status in relation to the largest annual change in percent density and dense area using mammograms available spanning 5.4 years, on average, using multivariable logistic regression and to the rate of mammographic density change using linear mixed-effects models. We considered effect modification by: mammographic density level of the earlier mammogram, the extent of family history, Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation (BOADICEA) risk strata, and menopausal status.</p><p><strong>Results: </strong>Cases (diagnosed < 60 years) had greater initial percent density and dense area levels and a slower rate of decline in dense area than controls. Women with stable mammographic density (≤ 10% annual change) had an increased breast cancer risk as compared with women whose largest mammographic density change was > 10% annual decline (e.g., Odds Ratio (OR) 2.34, 95% Confidence Interval (CI) 1.63-3.37 for dense area). Increasing vs. decreasing dense area was also associated with elevated risk, especially in women with the highest dense area levels at the earlier mammogram (OR: 2.56, 95%CI 1.50-4.36). Although generally similar across menopausal and familial risk categories, the associations of MD change with risk appeared stronger in pre-menopausal and lower-risk women.</p><p><strong>Conclusions: </strong>Women who maintain higher levels of mammographic density (i.e. do not decrease over time) or have increasing mammographic density over time have a higher risk of subsequent breast cancer than women with high mammographic density that decreases over time. These findings suggest potential for incorporating mammographic density trajectories in clinical risk assessment, and the importance of additional breast cancer monitoring in women not experiencing declines in mammographic density over time.</p>","PeriodicalId":49227,"journal":{"name":"Breast Cancer Research","volume":"26 1","pages":"166"},"PeriodicalIF":7.4,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11590558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142733949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Toll-Like receptor 3-mediated interferon-β production is suppressed by oncostatin m and a broader epithelial-mesenchymal transition program. Toll-Like 受体 3 介导的干扰素-β 生成受到 oncostatin m 和更广泛的上皮-间质转化程序的抑制。
IF 7.4 1区 医学
Breast Cancer Research Pub Date : 2024-11-26 DOI: 10.1186/s13058-024-01918-2
Noah M Chernosky, Ilaria Tamagno, Kelsey L Polak, E Ricky Chan, Xueer Yuan, Mark W Jackson
{"title":"Toll-Like receptor 3-mediated interferon-β production is suppressed by oncostatin m and a broader epithelial-mesenchymal transition program.","authors":"Noah M Chernosky, Ilaria Tamagno, Kelsey L Polak, E Ricky Chan, Xueer Yuan, Mark W Jackson","doi":"10.1186/s13058-024-01918-2","DOIUrl":"10.1186/s13058-024-01918-2","url":null,"abstract":"<p><strong>Background: </strong>Patients with Triple Negative Breast Cancer (TNBC) currently lack targeted therapies, and consequently face higher mortality rates when compared to patients with other breast cancer subtypes. The tumor microenvironment (TME) cytokine Oncostatin M (OSM) reprograms TNBC cells to a more stem-like/mesenchymal state, conferring aggressive cancer cell properties such as enhanced migration and invasion, increased tumor-initiating capacity, and intrinsic resistance to the current standards of care. In contrast to OSM, Interferon-β (IFN-β) promotes a more differentiated, epithelial cell phenotype in addition to its role as an activator of anti-tumor immunity. Importantly, OSM suppresses the production of IFN-β, although the mechanism of IFN-β suppression has not yet been elucidated.</p><p><strong>Methods: </strong>IFN-β production and downstream autocrine signaling were assessed via quantitative real-time PCR (qRT-PCR) and Western blotting in TNBC cells following exposure to OSM. RNA-sequencing (RNA-seq) was used to assess an IFN-β metagene signature, and to assess the expression of innate immune sensors, which are upstream activators of IFN-β. Cell migration was assessed using an in vitro chemotaxis assay. Additionally, TNBC cells were exposed to TGF-β1, Snail, and Zeb1, and IFN-β production and downstream autocrine signaling were assessed via RNA-seq, qRT-PCR, and Western blotting.</p><p><strong>Results: </strong>Here, we identify the repression of Toll-like Receptor 3 (TLR3), an innate immune sensor, as the key molecular event linking OSM signaling and the repression of IFN-β transcription, production, and autocrine IFN signaling. Moreover, we demonstrate that additional epithelial-mesenchymal transition-inducing factors, such as TGF-β1, Snail, and Zeb1, similarly suppress TLR3-mediated IFN-β production and signaling.</p><p><strong>Conclusions: </strong>Our findings provide a novel insight into the regulation of TLR3 and IFN-β production in TNBC cells, which are known indicators of treatment responses to DNA-damaging therapies. Furthermore, strategies to stimulate TLR3 in order to increase IFN-β within the TME may be ineffective in stem-like/mesenchymal cells, as TLR3 is strongly repressed. Rather, we propose that therapies targeting OSM or OSM receptor would reverse the stem-like/mesenchymal program and restore TLR3-mediated IFN-β production within the TME, facilitating improved responses to current therapies.</p>","PeriodicalId":49227,"journal":{"name":"Breast Cancer Research","volume":"26 1","pages":"167"},"PeriodicalIF":7.4,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11590466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142733952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A systematic review of candidate genes and their relevant pathways for metastasis among adults diagnosed with breast cancer. 对已确诊的成人乳腺癌转移候选基因及其相关通路进行系统回顾。
IF 7.4 1区 医学
Breast Cancer Research Pub Date : 2024-11-26 DOI: 10.1186/s13058-024-01914-6
Gina M Gehling, Miad Alfaqih, Lisiane Pruinelli, Angela Starkweather, Jennifer R Dungan
{"title":"A systematic review of candidate genes and their relevant pathways for metastasis among adults diagnosed with breast cancer.","authors":"Gina M Gehling, Miad Alfaqih, Lisiane Pruinelli, Angela Starkweather, Jennifer R Dungan","doi":"10.1186/s13058-024-01914-6","DOIUrl":"10.1186/s13058-024-01914-6","url":null,"abstract":"<p><strong>Background: </strong>Presently incurable, metastatic breast cancer is estimated to occur in as many as 30% of those diagnosed with early-stage breast cancer. Timely and accurate identification of those at risk for developing metastasis using validated biomarkers has the potential to have profound impact on overall survival rates. Our primary goal was to conduct a systematic review and synthesize the existing body of scientific knowledge on the candidate genes and their respective single nucleotide polymorphisms associated with metastasis-related outcomes among patients diagnosed with breast cancer. This knowledge is critical to inform future hypothesis-driven and validation research aimed at enhancing clinical decision-making for breast cancer patients.</p><p><strong>Methods: </strong>Using PRISMA guidelines, literature searches were conducted on September 13th, 2023, using PubMed and Embase databases. The systematic review protocol was registered with INPLASY (DOI: https://doi.org/10.37766/inplasy2024.8.0014 ). Covidence software was used to facilitate the screening and article extraction processes. Peer-reviewed articles were selected if authors reported on single nucleotide polymorphisms directly associated with metastasis among adults diagnosed with breast cancer.</p><p><strong>Findings: </strong>We identified 451 articles after 44 duplicates were removed resulting in 407 articles to be screened for study inclusion. Three reviewers completed the article screening process which resulted in 86 articles meeting the study inclusion criteria. Sampling varied across studies with the majority utilizing a case-control design (n = 75, 87.2%), with sample sizes ranging from 23 to 1,017 participants having mean age 50.65 ± 4.50 (min-max: 20-75). The synthesis of this internationally generated evidence revealed that the scientific area on the underlying biological contributions to breast cancer metastasis remains predominantly exploratory in nature (n = 74, 86%). Of the 12 studies with reported power analyses, only 9 explicitly stated the power values which ranged from 47.88 to 99%.</p><p><strong>Discussion: </strong>Understanding the underlying biological mechanisms contributing to metastasis is a critical component for precision oncological therapeutics and treatment approaches. Current evidence investigating the contribution of SNPs to the development of metastasis is characterized by underpowered candidate gene studies. To inform individualized precision health practices and improve breast cancer survival outcomes, future hypothesis-driven research is needed to replicate these associations in larger, more diverse datasets.</p>","PeriodicalId":49227,"journal":{"name":"Breast Cancer Research","volume":"26 1","pages":"165"},"PeriodicalIF":7.4,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11590482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142733946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization of novel small molecule inhibitors of estrogen receptor-activation function 2 (ER-AF2). 新型雌激素受体激活功能 2 (ER-AF2) 小分子抑制剂的特征。
IF 7.4 1区 医学
Breast Cancer Research Pub Date : 2024-11-26 DOI: 10.1186/s13058-024-01926-2
Jane Foo, Francesco Gentile, Shabnam Massah, Helene Morin, Kriti Singh, Joseph Lee, Jason Smith, Fuqiang Ban, Eric LeBlanc, Robert Young, Natalie Strynadka, Nada Lallous, Artem Cherkasov
{"title":"Characterization of novel small molecule inhibitors of estrogen receptor-activation function 2 (ER-AF2).","authors":"Jane Foo, Francesco Gentile, Shabnam Massah, Helene Morin, Kriti Singh, Joseph Lee, Jason Smith, Fuqiang Ban, Eric LeBlanc, Robert Young, Natalie Strynadka, Nada Lallous, Artem Cherkasov","doi":"10.1186/s13058-024-01926-2","DOIUrl":"10.1186/s13058-024-01926-2","url":null,"abstract":"<p><p>Up to 40% of patients with estrogen receptor (ER)-positive breast cancer will develop resistance against the majority of current ER-directed therapies. Resistance can arise through various mechanisms such as increased expression levels of coregulators, and key mutations acquired in the receptor's ligand binding domain rendering it constitutively active. To overcome these resistance mechanisms, we explored targeting the ER Activation Function 2 (AF2) site, which is essential for coactivator binding and activation. Using artificial intelligence and the deep docking methodology, we virtually screened > 1 billion small molecules and identified 290 potential AF2 binders that were then characterized and validated through an iterative screening pipeline of cell-based and cell-free assays. We ranked the compounds based on their ability to reduce the transcriptional activity of the estrogen receptor and the viability of ER-positive breast cancer cells. We identified a lead compound, VPC-260724, which inhibits ER activity at low micromolar range. We confirmed its direct binding to the ER-AF2 site through a PGC1α peptide displacement experiment. Using proximity ligation assays, we showed that VPC-260724 disrupts the interaction between ER-AF2 and the coactivator SRC-3 and reduces the expression of ER target genes in various breast cancer models including the tamoxifen resistant cell line TamR3. In conclusion, we developed a novel ER-AF2 binder, VPC-260724, which shows antiproliferative activity in ER-positive breast cancer models. The use of an ER-AF2 inhibitor in combination with current treatments may provide a novel complementary therapeutic approach to target treatment resistance in ER-positive breast cancer.</p>","PeriodicalId":49227,"journal":{"name":"Breast Cancer Research","volume":"26 1","pages":"168"},"PeriodicalIF":7.4,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11590367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142733947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信